Primary regulatory
SURMOUNT-5: Tirzepatide vs Semaglutide for Obesity: ClinicalTrials.gov
ClinicalTrials.gov registry for the SURMOUNT-5 Phase 3 head-to-head trial of tirzepatide versus semaglutide for obesity, sponsored by Eli Lilly.
ClinicalTrials.govPublished 2022-08-01Accessed 2026-07-08
Registry record
Source metadata
- Publisher
- ClinicalTrials.gov
- Source type
- Primary regulatory
- Registry ID
clinicaltrials-gov-surmount5
Source usage
Linked from 2 pages
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.